1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Trends in Therapeutic Partnering 2010-2015

Trends in Therapeutic Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 4330 pages

The Trends in Therapeutic Partnering 2010-2015 report provides the most comprehensive and in-depth insight into the 35 most popular therapeutic targets for partnering in the period 2010 to mid 2015.

The report provides a detailed understanding and analysis of the most popular therapeutic targets for partnering in the period 2010 to mid 2015. The majority of deals are discovery, preclinical and clinical stage whereby the licensee obtains a right or an option right to license or access the licensors compounds or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapeutic targets. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of therapeutic partnering trends since 2010, together with insight into which companies are active in each of the thirty five leading therapeutic areas.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of therapeutic dealmaking.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of therapeutic dealmaking since 2010, listing the top therapeutic areas for partnering by deal frequency and deal dollars committed by partnering companies.

Chapter 3 reviews the top pharma and biotech therapeutic partnering deals of 2010-2015 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to the leading therapeutic partnering companies, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with biopharma companies provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of each of the top 35 therapeutic target areas according to deal frequency during the period 2010-2015 provide everything required to assess the potential of the therapeutic area and its active partner companies. Each profile includes a partnering activity overview, deal financials (including headline, upfront and royalties rates, where available).

Each therapeutic profile provides a listing of partnering deals for the top fifiteen most active companies in each therapeutic area, and is accompanied by an appendix that provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners’ negiotated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 5,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to understand trends in therapeutic partnering, the most active therapeutic areas in terms of deal frequency and leading deal maker companies, and the deal terms and structures achieved in such therapeutic partnering deals.

Report scope


Trends in Therapeutic Partnering 2010-2015 is intended to provide the reader with an in-depth understanding of therapeutic partnering trends and structure of deals entered into by leading companies worldwide.


Trends in Therapeutic Partnering 2010-2015 includes:

Trends in therapeutic dealmaking in the biopharma industry since 2010
Analysis of therapeutic partnering deal structure
Access to over 5,000 therapeutic partnering deals
The top 35 therapeutic targets for partnering since 2009
The leading therapeutic partnering deals by value since 2010
Most active therapeutic partnering dealmakers since 2010

In Trends in Therapeutic Partnering 2010-2015, the available deals are listed by:

Most active companies in partnering for each therapeutic area
Headline value
Upfront payment
Royalty rate
Company A-Z

Each deal title links to online deal records of actual therapeutic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The Trends in Therapeutic Partnering 2010-2015 report provides comprehensive access to available deal records for over 5,000 therapeutic target partnering deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law'Trends in Therapeutic Partnering 2010- 2015 provides the reader with the following key benefits:

In-depth understanding of therapeutic partnering trends since 2010
Analysis of the top 35 therapeutic target areas for partnering and the deal structure
Identify the most active therapeutic partnering dealmakers since 2010
Comprehensive access to over 5,000 actual partnering deals as recorded at Current Agreement, together with contract documents if available
Detailed access to actual therapeutic partnering deals entered into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a therapeutic partnering agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Full listing of partnering deals by headline value, upfront payment, royalty rate and company A-Z

Table Of Contents

Trends in Therapeutic Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in therapeutic dealmaking activity

2.1. Introduction
2.2. Leading therapy partnering areas
2.3. Top therapeutic targets for partnering 2010-2015

Chapter 3 - Leading therapy deals by value

3.1. Introduction
3.2. Big pharma therapy partnering
3.3. Big biotech therapy partnering

Chapter 4 - Submitting opportunities to therapeutic target partner companies

4.1. How to submit an opportunity
4.2. Opportunity submission template
4.3. Sending emails
4.4. Face to face at partnering events
4.5. Online submission forms

Chapter 5 - Forthcoming therapeutic partnering events

5.1. Forthcoming events

Chapter 6 - Top 35 therapeutic partnering targets

6.1. Introduction
6.2. Therapeutic profiles
1. Diabetes
Diabetes partnering in numbers
Top diabetes partnering deals by value
Most active diabetes partnering companies
2. Pain CNS
Pain partnering in numbers
Top pain partnering deals by value
Most active pain partnering companies
3. Breast cancer
Breast cancer partnering in numbers
Top breast cancer partnering deals by value
Most active breast cancer partnering companies
4. Alzheimer's disease
Alzheimer's disease partnering in numbers
Top Alzheimer's disease partnering deals by value
Most active Alzheimer's disease partnering companies
5. Wound healing
Wound healing partnering in numbers
Top wound healing partnering deals by value
Most active wound healing partnering companies
6. HIV
HIV partnering in numbers
Top HIV partnering deals by value
Most active HIV partnering companies
7. Inflammation
Inflammation partnering in numbers
Top Inflammation partnering deals by value
Most active inflammation partnering companies
8. Leukemia
Leukemia partnering in numbers
Top leukemia partnering deals by value
Most active leukemia partnering companies
9. Prostate cancer
Prostate cancer partnering in numbers
Top prostate cancer partnering deals by value
Most active prostate cancer partnering companies
10. Solid tumor
Solid tumor partnering in numbers
Top solid tumors partnering deals by value
Most active solid tumor partnering companies
11. Parkinson's disease
Parkinson's disease partnering in numbers
Top Parkinson's disease partnering deals by value
Most active Parkinson's disease partnering companies
12. Lung cancer
Lung cancer partnering in numbers
Top lung cancer partnering deals by value
Most active lung cancer partnering companies
13. Colorectal cancer
Colorectal cancer partnering in numbers
Top colorectal cancer partnering deals by value
Most active colorectal cancer partnering companies
14. Nutrition and Vitamins
Nutrition and Vitamins partnering in numbers
Top nutrition and vitamins partnering deals by value
Most active nutrition and vitamin partnering companies
15. Influenza
Influenza partnering in numbers
Top influenza partnering deals by value
Most active influenza partnering companies
PATH (Appropriate Technology in Health)
16. Rheumatoid arthritis
Rheumatoid arthritis partnering in numbers
Top rheumatoid arthritis partnering deals by value
Most active rheumatoid arthritis partnering companies
17. Multiple sclerosis
Multiple sclerosis partnering in numbers
Top multiple sclerosis partnering deals by value
Most active multiple sclerosis partnering companies
18. Lymphoma
Lymphoma partnering in numbers
Top lymphoma partnering deals by value
Most active lymphoma partnering companies
19. Orthopedics
Orthopedics partnering in numbers
Top Orthopedics partnering deals by value
Most active Orthopedics partnering companies
20. Rare Genetics Disorders
Rare Genetics Disorders partnering in numbers
Top rare genetic disorders partnering deals by value
Most active rare genetic disorders partnering companies
21. Ovarian cancer
Ovarian cancer partnering in numbers
Top ovarian cancer partnering deals by value
Most active ovarian cancer partnering companies
22. Transplantation
Transplantation partnering in numbers
Top transplantation partnering deals by value
Most active transplantation partnering companies
23. Orphan Disease
Orphan Disease partnering in numbers
Top Orphan disease partnering deals by value
Most active orphan disease partnering companies
24. Spinal cord
Spinal cord partnering in numbers
Top spinal cord partnering deals by value
Most active spinal cord partnering companies
25. Obesity
Obesity partnering in numbers
Top obesity partnering deals by value
Most active obesity partnering companies
26. Accident and emergency
Accident and emergency partnering in numbers
Top Accident and emergency partnering deals by value
27. Pancreatic cancer
Pancreatic cancer partnering in numbers
Top pancreatic cancer partnering deals by value
Most active pancreatic cancer partnering companies
28. Tuberculosis
Tuberculosis partnering in numbers
Top tuberculosis partnering deals by value
Most active tuberculosis partnering companies
29. Hepatitis C
Hepatitis C partnering in numbers
Top hepatitis C partnering deals by value
Most active hepatitis C partnering companies
30. Other autoimmune disorders
Other autoimmune disorders partnering in numbers
Top other autoimmune disorders partnering deals by value
Most active other autoimmune disorders partnering companies
31. Melanoma
Melanoma partnering in numbers
Top melanoma partnering deals by value
Most active melanoma partnering companies
32. Congestive heart failure
Congestive heart failure partnering in numbers
Top congestive heart failure partnering deals by value
Most active congestive heart failure partnering companies
33. Cosmetics
Cosmetics partnering in numbers
Top cosmetics partnering deals by value
Most active cosmetics partnering companies
34. Multiple myeloma
Multiple myeloma partnering in numbers
Top Multiple myeloma partnering deals by value
Most active Multiple myeloma partnering companies
35. Asthma
Asthma partnering in numbers
Top asthma partnering deals by value
Most active asthma partnering companies

Chapter 7 - Resources
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering


See 3 separate volumes for the following appendices

Appendix volume 1

Appendix 1 - Diabetes deal directory - company A-Z
Appendix 2 - Pain deal directory - company A-Z
Appendix 3 - Breast cancer deal directory - company A-Z
Appendix 4 - Alzeimer's disease deal directory - company A-Z
Appendix 5 - Wound healing deal directory - company A-Z
Appendix 6 -HIV deal directory - company A-Z
Appendix 7 - Inflammation deal directory - company A-Z

Appendix volume 2

Appendix 8 - Leukemia deal directory - company A-Z
Appendix 9 - Prostate cancer deal directory - company A-Z
Appendix 10 - Solid tumors deal directory - company A-Z
Appendix 11 - Parkinson's disease deal directory - company A-Z
Appendix 12 - Lung cancer deal directory - company A-Z
Appendix 13 - Colorectal cancer deal directory - company A-Z
Appendix 14 - Nutrition and vitamins deal directory - company A-Z
Appendix 15 -Influenza deal directory - company A-Z
Appendix 16 -Rheumatoid arthritis deal directory - company A-Z
Appendix 17 - Multiple sclerosis deal directory - company A-Z

Appendix volume 3

Appendix 18 - Lymphoma deal directory - company A-Z
Appendix 19 - Orthopedics deal directory - company A-Z
Appendix 20 -Rare genetic disorders deal directory - company A-Z
Appendix 21 - Ovarian cancer deal directory - company A-Z
Appendix 22 - Transplantation deal directory - company A-Z
Appendix 23 - Orphan disease deal directory - company A-Z
Appendix 24 - Spinal cord deal directory - company A-Z
Appendix 25 - Obesity deal directory - company A-Z
Appendix 26 - Accident and Emergency deal directory - company A-Z
Appendix 27 - Pancreatic cancer deal directory - company A-Z
Appendix 28 - Tuberculosis deal directory - company A-Z
Appendix 29 - Hepatitis C deal directory - company A-Z
Appendix 30 - Other autoimmune disorders deal directory - company A-Z
Appendix 31 - Melanoma deal directory - company A-Z
Appendix 32 - Congestive heart failure deal directory - company A-Z
Appendix 33 - Cosmetics deal directory - company A-Z
Appendix 34 - Multiple myeloma deal directory - company A-Z
Appendix 35 - Asthma deal directory - company A-Z
Appendix 36 - Deal type definitions
Appendix 37 - Example contract document

TABLE OF FIGURES

Figure 1: Partnering trends by therapy area 2010-2015
Figure 2: Top most partnered therapeutics targets 2010-2015
Figure 3: Top partnered therapeutic targets by financial value 2010-2015
Figure 4: Leading big pharma therapy partnering deals by value, 2010-2015
Figure 5: Leading big biotech therapy partnering deals by value, 2010-2015
Figure 6: Typical partnering opportunity submission template
Figure 7: Diabetes: Partnering frequency 2010-2015
Figure 8: Diabetes: most active dealmakers
Figure 9: Diabetes: partnering deals by sector
Figure 10: Diabetes partnering deals by type
Figure 11: Diabetes partnering deals by technology type
Figure 12: Diabetes artnering deals by stage of development
Figure 13: Diabetes partnering deals by headline value
Figure 14: Diabetes: partnering deals by upfront payment
Figure 15: Diabetes partnering deals by royalty rate
Figure 16: Diabetes: partnering deals 2010-2015 - most active companies
Figure 17: Pain: Partnering frequency 2010-2015
Figure 18: Pain partnering most active dealmakers
Figure 19: Pain partnering deals by sector
Figure 20: Pain partnering deals by type
Figure 21: Pain partnering deals by technology type
Figure 22: Pain partnering deals by stage of development
Figure 23: Pain partnering deals by headline value
Figure 24: Pain partnering deals by upfront payment
Figure 25: Pain partnering deals by royalty rate
Figure 26: Pain partnering deals 2010-2015 by most active companies
Figure 27: Breast cancer: Partnering frequency 2010-2015
Figure 28: Breast cancer most active dealmakers
Figure 29: Breast cancer partnering deals by sector
Figure 30: Breast cancer partnering deals by type
Figure 31: Breast cancer partnering deals by technology type
Figure 32: Breast cancer partnering deals by stage of development
Figure 33: Breast cancer partnering deals by headline value
Figure 34: Breast cancer partnering deals by upfront payment
Figure 35: Breast cancer partnering deals by royalty rate
Figure 36: Breast cancer partnering deals 2010-2015 by most active companies
Figure 37: Alzheimer's disease: Partnering frequency 2010-2015
Figure 38: Alzheimer's disease most active dealmakers
Figure 39: Alzheimer's disease partnering deals by sector
Figure 40: Alzheimer's disease partnering deals by type
Figure 41: Alzheimer's disease partnering deals by technology type
Figure 42: Alzheimer's disease partnering deals by stage of development
Figure 43: Alzheimer's disease partnering deals by headline value
Figure 44: Alzheimer's disease partnering deals by upfront payment
Figure 45: Alzheimer's disease partnering deals by royalty rate
Figure 46: Alzheimer's partnering deals 2010-2015 by most active companies
Figure 47: Wound healing: Partnering frequency 2010-2015
Figure 48: Wound healing most active dealmakers
Figure 49: Wound healing partnering deals by sector
Figure 50: Wound healing partnering deals by type
Figure 51: Wound healing partnering deals by technology type
Figure 52: Wound healing partnering deals by stage of development
Figure 53: Wound healing partnering deals by headline value
Figure 54: Wound healing partnering deals by upfront payment
Figure 55: Wound healing partnering deals by royalty rate
Figure 56: Wound healing partnering deals 2010-2015 by most active companies
Figure 57: HIV: Partnering frequency 2010-2015
Figure 58: HIV most active dealmakers
Figure 59: HIV partnering deals by sector
Figure 60: HIV partnering deals by type
Figure 61: HIV partnering deals by technology type
Figure 62: HIV partnering deals by stage of development
Figure 63: HIV partnering deals by headline value
Figure 64: HIV partnering deals by upfront payment
Figure 65: HIV partnering deals by royalty rate
Figure 66: HIV partnering deals 2010-2015 by most active companies
Figure 67: Inflammation: Partnering frequency 2010-2015
Figure 68: Inflammation most active dealmakers
Figure 69: Inflammation partnering deals by industry sector
Figure 70: Inflammation partnering deals by type
Figure 71: Inflammation partnering deals by technology type
Figure 72: Inflammation partnering deals by stage of development
Figure 73: Inflammation partnering deals by headline value
Figure 74: Inflammation partnering deals by upfront payment
Figure 75: Inflammation partnering deals by royalty rate
Figure 76: Inflammation partnering deals 2010-2015 by most active companies
Figure 77: Leukemia: Partnering frequency 2010-2015
Figure 78: Leukemia most active dealmakers
Figure 79: Leukemia partnering deals by industry sector
Figure 80: Leukemia partnering deals by type
Figure 81: Leukemia partnering deals by technology type
Figure 82: Leukemia partnering deals by stage of development
Figure 83: Leukemia partnering deals by headline value
Figure 84: Leukemia partnering deals by upfront payment
Figure 85: Leukemia partnering deals by royalty rate
Figure 86: Leukemia partnering deals 2010-2015 by most active companies
Figure 87: Prostate cancer: Partnering frequency 2010-2015
Figure 88: Prostate cancer most active dealmakers
Figure 89: Prostate cancer partnering deals by industry sector
Figure 90: Prostate cancer partnering deals by type
Figure 91: Prostate cancer partnering deals by technology type
Figure 92: Prostate cancer partnering deals by stage of development
Figure 93: Prostate cancer partnering deals by headline value
Figure 94: Prostate cancer partnering deals by upfront payment
Figure 95: Prostate cancer partnering deals by royalty rate
Figure 96: Prostate cancer partnering deals 2010-2015 by most active companies
Figure 97: Solid tumor: Partnering frequency 2010-2015
Figure 98: Solid tumor most active dealmakers
Figure 99: Solid tumor partnering deals by industry sector
Figure 100: Solid tumor partnering deals by type
Figure 101: Soid tumor partnering deals by technology type
Figure 102: Solid tumor partnering deals by stage of development
Figure 103: Solid tumor partnering deals by headline value
Figure 104: Solid tumor partnering deals by upfront payment
Figure 105: Solid tumor partnering deals by royalty rate
Figure 106: Solid tumor partnering deals 2010-2015 by most active companies
Figure 107: Parkinson's disease: Partnering frequency 2010-2015
Figure 108: Parkinson's disease most active dealmakers
Figure 109: Parkinson's disease partnering deals by industry sector
Figure 110: Parkinson's disease partnering deals by type
Figure 111: Parkinson's disease partnering deals by technology type
Figure 112: Parkinson's disease partnering deals by stage of development
Figure 113: Parkinson's disease partnering deals by headline value
Figure 114: Parkinson's disease partnering deals by upfront payment
Figure 115: Parkinson's disease partnering deals by royalty rate
Figure 116: Parkinson's disease partnering deals 2010-2015 by most active companies
Figure 117: Lung cancer: Partnering frequency 2010-2015
Figure 118: Lung cancer most active dealmakers
Figure 119: Lung cancer partnering deals by sector
Figure 120: Lung cancer partnering deals by type
Figure 121: Lung cancer partnering deals by technology type
Figure 122: Lung cancer partnering deals by stage of development
Figure 123: Lung cancer partnering deals by headline value
Figure 124: Lung cancer partnering deals by upfront payment
Figure 125: Lung cancer partnering deals 2010-2015 by most active companies
Figure 126: Colorectal cancer: Partnering frequency 2010-2015
Figure 127: Colorectal cancer most active dealmakers
Figure 128: Colorectal cancer partnering deals by industry sector
Figure 129: Colorectal cancer partnering deals by type
Figure 130: Colorectal cancer partnering deals by technology type
Figure 131: Colorectal cancer partnering deals by stage of development
Figure 132: Colorectal cancer partnering deals by headline value
Figure 133: Coloretal cancer partnering deals by upfront payment
Figure 134: Colorectal cancer partnering deals by royalty rate
Figure 135: Colorectal cancer partnering deals 2010-2015 by most active companies
Figure 136: Nutrition and Vitamins: Partnering frequency 2010-2015
Figure 137: Nutrition and Vitamins most active dealmakers
Figure 138: Nutrition and Vitamins partnering deals by sector
Figure 139: Nutrition and Vitamins partnering deals by type
Figure 140: Nutrition and Vitamins partnering deals by technology type
Figure 141: Nutrition and Vitamins partnering deals by stage of development
Figure 142: Nutrition and Vitamins partnering deals by headline value
Figure 143: Nutrition and Vitamins partnering deals by upfront payment
Figure 144: Nutrition and Vitamins partnering deals by royalty rate
Figure 145: Nutrition and Vitamins partnering deals 2010-2015 by most active companies
Figure 146: Influenza: Partnering frequency 2010-2015
Figure 147: Influenza most active dealmakers
Figure 148: Influenza partnering deals by industry sector
Figure 149: Influenza partnering deals by type
Figure 150: Influenza partnering deals by technology type
Figure 151: Influenza partnering deals by stage of development
Figure 152: Influenza partnering deals by headline value
Figure 153: Influenza partnering deals by upfront payment
Figure 154: Influenza partnering deals by royalty rate
Figure 155: Influenza partnering deals 2010-2015 by most active companies
Figure 156: Rheumatoid arthritis: Partnering frequency 2010-2015
Figure 157: Rheumatoid arthritis most active dealmakers
Figure 158: Rheumatoid arthritis partnering deals by industry sector
Figure 159: Rheumatoid arthritis partnering deals by type
Figure 160: Rheumatoid arthritis partnering deals by technology type
Figure 161: Rheumatoid arthritis partnering deals by stage of development
Figure 162: Rheumatoid arthritis partnering deals by headline value
Figure 163: Rheumatoid arthritis partnering deals by upfront payment
Figure 164: Rheumatoid arthritis partnering deals by royalty rate
Figure 165: Rheumatoid arthritis partnering deals 2010-2015 by most active companies
Figure 166: Multiple sclerosis: Partnering frequency 2010-2015
Figure 167: Multiple sclerosis most active dealmakers
Figure 168: Multiple sclerosis partnering deals by industry sector
Figure 169: Multiple sclerosis partnering deals by type
Figure 170: Multiple sclerosis partnering deals by technology type
Figure 171: Multiple sclerosis partnering deals by stage of development
Figure 172: Multiple sclerosis partnering deals by headline value
Figure 173: Multiple sclerosis partnering deals by upfront payment
Figure 174: Multiple sclerosis partnering deals by royalty rate
Figure 175: Multiple sclerosis partnering deals 2010-2015 by most active companies
Figure 176: Lymphoma: Partnering frequency 2010-2015
Figure 177: Lymphoma most active dealmakers
Figure 178: Lymphoma partnering deals by industry sector
Figure 179: Lymphoma partnering deals by type
Figure 180: Lymphoma partnering deals by technology type
Figure 181: Lymphoma partnering deals by stage of development
Figure 182: Lymphoma partnering deals by headline value
Figure 183: Lymphoma partnering deals by upfront payment
Figure 184: Lymphoma partnering deals by royalty rate
Figure 185: Lymphoma partnering deals 2010-2015 by most active companies
Figure 186: Orthopedics: Partnering frequency 2010-2015
Figure 187: Orthopedics most active dealmakers
Figure 188: Orthopedics partnering deals by industry sector
Figure 189: Orthopedics partnering deals by type
Figure 190: Orthopedics partnering deals by technology type
Figure 191: Orthopedics partnering deals by stage of development
Figure 192: Orthopedics partnering deals by headline value
Figure 193: Orthopedics partnering deals by upfront payment
Figure 194: Orthopedics partnering deals by royalty rate
Figure 195: Orthopedics partnering deals 2010-2015 by most active companies
Figure 196: Rare genetic disorders: Partnering frequency 2010-2015
Figure 197: Rare genetic disorders most active dealmakers
Figure 198: Rare genetic disorders partnering deals by industry sector
Figure 199: Rare genetic disorders partnering deals by type
Figure 200: Rare genetic disorders partnering deals by technology type
Figure 201: Rare genetic disorders partnering deals by stage of development
Figure 202: Rare genetic disorders partnering deals by headline value
Figure 203: Rare genetic disorders partnering deals by upfront payment
Figure 204: Rare genetic disorders partnering deals by royalty rate
Figure 205: Rare genetic disorders partnering deals 2010-2015 by most active companies
Figure 206: Ovarian cancer: Partnering frequency 2010-2015
Figure 207: Ovarian cancer most active dealmakers
Figure 208: Ovarian cancer partnering deals by industry sector
Figure 209: Ovarian cancer partnering deals by type
Figure 210: Ovarian cancer partnering deals by technology type
Figure 211: Ovarian cancer partnering deals by stage of development
Figure 212: Ovarian cancer partnering deals by headline value
Figure 213: Ovarian cancer partnering deals by upfront payment
Figure 214: Ovarian cancer partnering deals 2010-2015 by most active companies
Figure 215: Transplantation: Partnering frequency 2010-2015
Figure 216: Transplantation most active dealmakers
Figure 217: Transplantation partnering deals by industry sector
Figure 218: Transplantation partnering deals by type
Figure 219: Transplantation partnering deals by technology type
Figure 220: Transplantation partnering deals by stage of development
Figure 221: Transplantation partnering deals by headline value
Figure 222: Transplantation partnering deals by upfront payment
Figure 223: Transplantation partnering deals by royalty rate
Figure 224: Transplantation partnering deals 2010-2015 by most active companies
Figure 225: Orphan disease: Partnering frequency 2010-2015
Figure 226: Orphan disease most active dealmakers
Figure 227: Orphan disease partnering deals by industry sector
Figure 228: Orphan disease partnering deals by type
Figure 229: Orphan disease partnering deals by technology type
Figure 230: Orphan disease partnering deals by stage of development
Figure 231: Orphan disease partnering deals by headline value
Figure 232: Orphan disease partnering deals by upfront payment
Figure 233: Orphan disease partnering deals by royalty rate
Figure 234: Orphan disease partnering deals 2010-2015 by most active companies
Figure 235: Spinal cord: Partnering frequency 2010-2015
Figure 236: Spinal cord most active dealmakers
Figure 237: Spinal cord partnering deals by industry sector
Figure 238: Spinal cord partnering deals by type
Figure 239: Spinal cord partnering deals by technology type
Figure 240: Spinal cord partnering deals by stage of development
Figure 241: Spinal cord partnering deals by headline value
Figure 242: Spinal cord partnering deals by upfront payment
Figure 243: Spinal cord partnering deals by royalty rate
Figure 244: Spinal cord partnering deals 2010-2015 by most active companies
Figure 245: Obesity: Partnering frequency 2010-2015
Figure 246: Obesity most active dealmakers
Figure 247: Obesity partnering deals by industry sector
Figure 248: Obesity partnering deals by type
Figure 249: Obesity partnering deals by technology type
Figure 250: Obesity partnering deals by stage of development
Figure 251: Obesity partnering deals by headline value
Figure 252: Obesity partnering deals by upfront payment
Figure 253: Obesity partnering deals by royalty rate
Figure 254: Obesity partnering deals 2010-2015 by most active companies
Figure 255: Accident and emergency: Partnering frequency 2010-2015
Figure 256: Accident and emergency most active dealmakers
Figure 257: Accident and emergency partnering deals by industry sector
Figure 258: Accident and emergency partnering deals by type
Figure 259: Accident and emergency partnering deals by technology type
Figure 260: Accident and emergency partnering deals by stage of development
Figure 261: Accident and emergency partnering deals by headline value
Figure 262: Accident and emergency partnering deals by upfront payment
Figure 263: Accident and emergency partnering deals 2010-2015 by most active companies
Figure 264: Pancreatic cancer: Partnering frequency 2010-2015
Figure 265: Pancreatic cancer most active dealmakers
Figure 266: Pancreatic cancer partnering deals by industry sector
Figure 267: Pancreatic cancer partnering deals by type
Figure 268: Pancreatic cancer partnering deals by technology type
Figure 269: Pancreatic cancer partnering deals by stage of development
Figure 270: Pancreatic cancer partnering deals by headline value
Figure 271: Pancreatic cancer partnering deals by upfront payment
Figure 272: Pancreatic cancer partnering deals 2010-2015 by most active companies
Figure 273: Tuberculosis: Partnering frequency 2010-2015
Figure 274: Tuberculosis most active dealmakers
Figure 275: Tuberculosis partnering deals by industry sector
Figure 276: Tuberculosis partnering deals by type
Figure 277: Tuberculosis partnering deals by technology type
Figure 278: Tuberculosis partnering deals by stage of development
Figure 279: Tuberculosis partnering deals by headline value
Figure 280: Tuberculosis partnering deals by upfront payment
Figure 281: Tuberculosis partnering deals 2010-2015 by most active companies
Figure 282: Hepatitis C: Partnering frequency 2010-2015
Figure 283: Hepatitis C most active dealmakers
Figure 284: Hepatitis C partnering deals by industry sector
Figure 285: Hepatitis C partnering deals by type
Figure 286: Hepatitis C partnering deals by technology type
Figure 287: Hepatitis C partnering deals by stage of development
Figure 288: Hepatitis C partnering deals by headline value
Figure 289: Hepatitis C partnering deals by upfront payment
Figure 290: Hepatitis C partnering deals 2010-2015 by most active companies
Figure 291: Other autoimmune disorders: Partnering frequency 2010-2015
Figure 292: Other autoimmune disorders most active dealmakers
Figure 293: Other autoimmune disorders partnering deals by industry sector
Figure 294: Other autoimmune disorders partnering deals by type
Figure 295: Other autoimmune disorders partnering deals by technology type
Figure 296: Other autoimmune disorders partnering deals by stage of development
Figure 297: Other autoimmune disorders partnering deals by headline value
Figure 298: Other autoimmune disorders partnering deals by upfront payment
Figure 299: Other autoimmune disorders partnering deals by royalty rate
Figure 300: Other autoimmune disorders partnering deals 2010-2015 by most active companies
Figure 301: Melanoma: Partnering frequency 2010-2015
Figure 302: Melanoma most active dealmakers
Figure 303: Melanoma partnering deals by industry sector
Figure 304: Melanoma partnering deals by type
Figure 305: Melanoma partnering deals by technology type
Figure 306: Melanoma partnering deals by stage of development
Figure 307: Melanoma partnering deals by headline value
Figure 308: Melanoma partnering deals by upfront payment
Figure 309: Melanoma partnering deals by royalty rate
Figure 310: Melanoma partnering deals 2010-2015 by most active companies
Figure 311: Congestive heart failure: Partnering frequency 2010-2015
Figure 312: Congestive heart failure most active dealmakers
Figure 313: Congestive heart failure partnering deals by industry sector
Figure 314: Congestive heart failure partnering deals by type
Figure 315: Congestive heart failure partnering deals by technology type
Figure 316: Congestive heart failure partnering deals by stage of development
Figure 317: Congestive heart failure partnering deals by headline value
Figure 318: Congestive heart failure partnering deals by upfront payment
Figure 319: Congestive heart failure partnering deals by royalty rate
Figure 320: Congestive heart failure partnering deals 2010-2015 by most active companies
Figure 321: Cosmetics: Partnering frequency 2010-2015
Figure 322: Cosmetics most active dealmakers
Figure 323: Cosmetics partnering deals by industry sector
Figure 324: Cosmetics partnering deals by type
Figure 325: Cosmetics partnering deals by technology type
Figure 326: Cosmetics partnering deals by stage of development
Figure 327: Cosmetics partnering deals by headline value
Figure 328: Cosmetics partnering deals by upfront payment
Figure 329: Cosmetics partnering deals by royalty rate
Figure 330: Cosmetics partnering deals 2010-2015 by most active companies
Figure 331: Multiple myeloma: Partnering frequency 2010-2015
Figure 332: Multiple myeloma most active dealmakers
Figure 333: Multiple myeloma partnering deals by industry sector
Figure 334: Multiple myeloma partnering deals by type
Figure 335: Multiple myeloma partnering deals by technology type
Figure 336: Multiple myeloma artnering deals by stage of development
Figure 337: Multiple myeloma partnering deals by headline value
Figure 338: Multiple myeloma partnering deals by upfront payment
Figure 339: Multiple myeloma partnering deals by royalty rate
Figure 340: Multiple myeloma partnering deals 2010-2015 by most active companies
Figure 341: Asthma: Partnering frequency 2010-2015
Figure 342: Asthma most active dealmakers
Figure 343: Asthma partnering deals by industry sector
Figure 344: Asthma partnering deals by type
Figure 345: Asthma partnering deals by technology type
Figure 346: Asthma partnering deals by stage of development
Figure 347: Asthma partnering deals by headline value
Figure 348: Asthma partnering deals by upfront payment
Figure 349: Asthma partnering deals by royalty rate
Figure 350: Asthma partnering deals 2010-2015 by most active companies
Figure 351: Online partnering resources

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.